Cash, cash equivalents and marketable securities were $555.3M as of September 30, compared to $754.4M as of December 31, 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- XENE Upcoming Earnings Report: What to Expect?
- Xenon Pharmaceuticals’ Phase 3 Study on Azetukalner: A Potential Game-Changer for Major Depressive Disorder
- Xenon Pharmaceuticals’ Phase 3 Study on Azetukalner: A Potential Game-Changer in Depression Treatment
- Xenon Pharmaceuticals’ XEN1101 Trial: A Promising Step in Seizure Treatment
- Xenon Pharmaceuticals Advances Bipolar Depression Treatment with Azetukalner Study